

**Informazioni personali:**

Nome e cognome: Giacomo Mulinacci

Data di nascita: 19 Marzo 1992

Luogo di nascita: Milano

CF: MLNGCM92C19F205P

Istruzione e formazione:

2011: Diploma di Maturità liceo scientifico Albert Einstein, Milano;

2018: Diploma di Laurea Magistrale In “*MD Course di Medicina e Chirurgia presso Università Vita-Salute San Raffaele*”, Milano (voto 110 e Lode e menzione accademica). Tesi di Laurea: “Early signs of retinal dysfunction in Type 1 Diabetic patients, the emergence of a subclinical stage of retinopathy?”;

08/11/2023: Conseguimento titolo di Specializzazione in Malattie Dell’Apparato Digerente presso l’Università Degli Studi di Milano-Bicocca (voto 70 e Lode). Tesi di Specializzazione: “*Ultrasound muscle assessment for sarcopenia screening in patients with Inflammatory Bowel Disease: a single-center, prospective study (SarcUS-IBD)*”.

Esperienza universitaria/specializzazione:

Novembre 2016-Gennaio 2018:

- Internato c/o Reparto di Endocrinologia e Malattie del Metabolismo, direttore Prof. Emanuele Bosi;
- Internato di ricerca c/o DRI (Diabetes Research Unit), settore complicanze del diabete, direttore dr. Gianpaolo Zerbini.

Novembre 2019-Novembre 2023: Medico specializzando in Malattie Dell’Apparato Digerente presso l’Università degli Studi di Bicocca. Capacità maturate:

- Gestione dei pazienti ricoverati con patologie gastrointestinali acute e croniche
- Esecuzione in autonomia di esofagogastroduodenoscopia e colonscopie diagnostiche ed interventistiche (polipectomie, mucosectomie, trattamento di varici, trattamento di sanguinamenti gastrointestinali)
- Gestione ambulatoriale di pazienti con patologie gastrointestinali ed epatiche

Esperienze all'estero:

Febbraio- Giugno 2018: Internato formativo c/o Barbara Davis Centre For Childhood Diabetes, Colorado, USA. Tutor durante il periodo in USA: dr. Shah Viral e Prof. Satish Garg.

Pubblicazioni:

Mulinacci G et al. Risk stratification in primary sclerosing cholangitis. *Minerva Gastroenterol Dietol.* 2020 Dec 10.

Mulinacci G et al. Old and novel prognostic biomarkers in primary biliary cholangitis. *Expert Opin Orphan Drugs.* 2020.

Mulinacci G et al. Takayasu arteritis and primary sclerosing cholangitis: A casual association or different phenotypes of the same disease? *J Transl Autoimmun.* 2021 Sep 21

Mulinacci G et al. Glycemic Outcomes with Early Initiation of Continuous Glucose Monitoring System in Recently Diagnosed Patients with Type 1 Diabetes. *Diabetes Technol Ther.* 2019 Jan;21

Mulinacci G, et al. New insights on the role of human leukocyte antigen complex in primary biliary cholangitis. *Front Immunol.* 2022 Aug 31;13:975115. doi: 10.3389/fimmu.2022.975115.

Massironi S, **Mulinacci G**, Allocca M, Peyrin-Biroulet L, Danese S. Inflammation and malnutrition in inflammatory bowel disease. *Lancet Gastroenterol Hepatol.* 2023 Jun;8(6):579-590. doi: 10.1016/S2468-1253(23)00011-0.

Massironi S, **Mulinacci G**, Gallo C, et al. The oft-overlooked cardiovascular complications of inflammatory bowel disease. *Expert Rev Clin Immunol.* 2023 Apr;19(4):375-391. doi: 10.1080/1744666X.2023.2174971.

Massironi S, **Mulinacci G**, Gallo C, et al. Mechanistic Insights into Eosinophilic Esophagitis: Therapies Targeting Pathophysiological Mechanisms. *Cells.* 2023 Oct 18;12(20):2473. doi: 10.3390/cells12202473.

Sara Massironi, Lorena Pirola, **Giacomo Mulinacci**, et al. Use of IBD Drugs in Patients With Hepatobiliary Comorbidities: Tips and Tricks, *Inflammatory Bowel Diseases*, 2022;, izac189, <https://doi.org/10.1093/ibd/izac189>

Massironi S, ... **Mulinacci G**, et al. Eosinophilic esophagitis: does age matter? *Expert Rev Clin Immunol.* 2023 Oct 23:1-13. doi: 10.1080/1744666X.2023.2274940.

Viganò C, Palermo A, **Mulinacci G**, et al. Prevalence of Disease-Related Malnutrition and Micronutrients Deficit in Patients with Inflammatory Bowel Disease: A Multicentric Cross-Sectional Study by the GSMII (Inflammatory Bowel Disease Study Group). *Inflamm Bowel Dis.* 2023 Aug 3;izad146. doi: 10.1093/ibd/izad146.

L. Cristoferi, M. Porta, D.P. Bernasconi, F. Leonardi, **G. Mulinacci**, A. Palermo, A. Gerussi, C. Gallo, M. Scaravaglio, E. Stucchi, C. Maino, D. Ippolito, D. D'Amato, C. Ferreira, M. Mavar, R. Banerjee, L. Antolini, M.G. Valsecchi, S. Fagioli, P. Invernizzi, M. Carbone. Radiomics-based model for outcome prediction in primary sclerosing cholangitis. *Digestive and liver disease.* 2022 Mar 01. <https://doi.org/10.1016/j.dld.2022.01.023>

A De Vincentis **G Mulinacci**... P Invernizzi, U Vespasiani-Gentilucci, M Carbone. Predictors of Serious Adverse Event and Non-response in Cirrhotic Patients With Primary Biliary Cholangitis under Obeticholic Acid. *DLD.* 2022 Mar 01.

Viganò C, **Mulinacci G**, Palermo A et al. Impact of COVID-19 on inflammatory bowel disease practice and perspectives for the future. *World J Gastroenterol.* 2021 Sep 7

Conti CB, **Mulinacci G**, Salerno R, Dinelli ME, Grassia R. Applications of endoscopic ultrasound elastography in pancreatic diseases: From literature to real life. *World J Gastroenterol.* 2022;28(9):909-917. doi:10.3748/wjg.v28.i9.909

Conti CB, Frego R, Redaelli AE, Maino M, **Mulinacci G**, Dinelli ME. Single-use Albarran module: A removable elevator system to enhance safety in biliary endoscopy? *Endosc Int Open.* 2021 Dec 14

L. Cristoferi, M. Porta, D.P. Bernasconi, F. Leonardi, **G. Mulinacci**, et al Radiomics-based model for outcome prediction in primary sclerosing cholangitis. *Digestive and liver disease.* 2022 Mar 01. DOI: <https://doi.org/10.1016/j.dld.2022.01.023>

Cristoferi L, Calvaruso V, Overi D, **Mulinacci G**, et al. Italian PBC Registry. Accuracy of Transient Elastography in Assessing Fibrosis at Diagnosis in Naïve Patients With Primary Biliary Cholangitis: A Dual Cut-Off Approach. *Hepatology.* 2021 Sep

Pirola L, Palermo A, **Mulinacci G**, Ratti L, Fichera M, Invernizzi P, Viganò C, Massironi S. Acute mesenteric ischemia and small bowel imaging findings in COVID-19: A comprehensive review of the literature. *World J Gastrointest Surg.* 2021 Jul 27

Palermo A, Gerussi A, **Mulinacci G**, Invernizzi P, Carbone M. Identifying Racial Disparities in Primary Biliary Cholangitis Patients: A Step Toward Achieving Equitable Outcomes Among All. *Dig Dis Sci.* 2020 Aug 13

D. D'Amato....**G. Mulinacci**...P. Invernizzi, M. Carbone, U. Vespasiani-Gentilucci on behalf of the Italian PBC Registry and the Club Epatologi Ospedalieri (CLEO)/Associazione Italiana Gastroenterologi ed Endoscopisti Digestivi Ospedalieri (AIGO) PBC Study Group. Real-world experience with obeticholic acid in patients with primary biliary cholangitis. Published:January 25, 2021

A.Coppadoro ...**G. Mulinacci**, G.Bellani, G.Foti. Helmet CPAP to Treat Hypoxic Pneumonia Outside the ICU: An Observational Study During the COVID-19 Outbreak. *Critical Care.* 2020.

Sacconi R, Casaluci M, Borrelli E, **Mulinacci G**, Lamanna F, Gelormini F, Carnevali A, Querques L, Zerbini G, Bandello F, Querques G. Multimodal Imaging Assessment of Vascular and Neurodegenerative Retinal Alterations in Type 1 Diabetic Patients without Fundoscopic Signs of Diabetic Retinopathy. *J Clin Med.* 2019 Sep 8;8(9):1409

Sacconi R, Lamanna F, Borrelli E, **Mulinacci G**, Casaluci M, Gelormini F, Carnevali A, Querques L, Zerbini G, Bandello F, Querques G. Morphofunctional analysis of the retina in patients with type 1 diabetes without complications after 30 years of disease. Sci Rep. 2020 Jan 14;10(1):206. doi: 10.1038/s41598-019-57034-1. PMID: 31937811; PMCID: PMC6959306

Esperienza lavorative:

Marzo-Aprile 2019: Collaborazione lavorativa con RSA San Felice, Segrate, Milano;

Marzo-Ottobre 2019: Collaborazione lavorativa con Società Med Più

Lingue parlate

Lingua madre: Italiano

Altre: Inglese (certificazione IELTS voto 7) e spagnolo (livello base)

Giacomo Mulinacci

16/01/2024